Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy

N. Bruyniks, R. E. Nappi, C. Castelo-Branco, T. J. De Villiers, J. Simon

Research output: Contribution to journalArticle

Abstract

Objectives To determine whether assessment of all moderate-to-severe symptoms at baseline gives a more accurate evaluation of the treatment effect of ospemifene in vulvovaginal atrophy (VVA) than the most bothersome symptom (MBS) approach.Methods Data were pooled from two pivotal phase-III clinical trials evaluating the efficacy and safety of oral ospemifene 60 mg/day for the treatment of symptoms of VVA (n = 1463 subjects). Symptoms of vaginal dryness, dyspareunia, and vaginal and/or vulvar irritation/itching reported as moderate or severe at baseline were evaluated. Clinically relevant differences between ospemifene and placebo were analyzed using a four-point severity scoring system and presented as improvement, substantial improvement, or relief.Results Subjects in these studies reported statistically significant improvement, substantial improvement, and relief for vaginal dryness (p <0.00001), dyspareunia (p <0.001) and statistically significant improvement and relief for vaginal and/or vulvar irritation/itching (p <0.01) from baseline to week 12 with ospemifene compared with placebo. A similar trend was observed for women who reported substantial improvement of vaginal and/or vulvar irritation/itching.Conclusions For drug registration purposes, the use of the MBS model is appealing because of its simplicity and ease of scientific validation. However, the MBS model may underestimate the total magnitude of the clinical benefit of ospemifene treatment for symptomatic women suffering from VVA.

Original languageEnglish
Pages (from-to)60-65
Number of pages6
JournalClimacteric
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 2 2016

Fingerprint

Atrophy
Pruritus
Dyspareunia
Placebos
Phase III Clinical Trials
Therapeutics
Ospemifene
Safety
Pharmaceutical Preparations

Keywords

  • ospemifene
  • randomized clinical trials
  • Vulvar and vaginal atrophy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. / Bruyniks, N.; Nappi, R. E.; Castelo-Branco, C.; De Villiers, T. J.; Simon, J.

In: Climacteric, Vol. 19, No. 1, 02.01.2016, p. 60-65.

Research output: Contribution to journalArticle

Bruyniks, N. ; Nappi, R. E. ; Castelo-Branco, C. ; De Villiers, T. J. ; Simon, J. / Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. In: Climacteric. 2016 ; Vol. 19, No. 1. pp. 60-65.
@article{60f8b0b230fa40b8b29c3c83658f592f,
title = "Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy",
abstract = "Objectives To determine whether assessment of all moderate-to-severe symptoms at baseline gives a more accurate evaluation of the treatment effect of ospemifene in vulvovaginal atrophy (VVA) than the most bothersome symptom (MBS) approach.Methods Data were pooled from two pivotal phase-III clinical trials evaluating the efficacy and safety of oral ospemifene 60 mg/day for the treatment of symptoms of VVA (n = 1463 subjects). Symptoms of vaginal dryness, dyspareunia, and vaginal and/or vulvar irritation/itching reported as moderate or severe at baseline were evaluated. Clinically relevant differences between ospemifene and placebo were analyzed using a four-point severity scoring system and presented as improvement, substantial improvement, or relief.Results Subjects in these studies reported statistically significant improvement, substantial improvement, and relief for vaginal dryness (p <0.00001), dyspareunia (p <0.001) and statistically significant improvement and relief for vaginal and/or vulvar irritation/itching (p <0.01) from baseline to week 12 with ospemifene compared with placebo. A similar trend was observed for women who reported substantial improvement of vaginal and/or vulvar irritation/itching.Conclusions For drug registration purposes, the use of the MBS model is appealing because of its simplicity and ease of scientific validation. However, the MBS model may underestimate the total magnitude of the clinical benefit of ospemifene treatment for symptomatic women suffering from VVA.",
keywords = "ospemifene, randomized clinical trials, Vulvar and vaginal atrophy",
author = "N. Bruyniks and Nappi, {R. E.} and C. Castelo-Branco and {De Villiers}, {T. J.} and J. Simon",
year = "2016",
month = "1",
day = "2",
doi = "10.3109/13697137.2015.1113517",
language = "English",
volume = "19",
pages = "60--65",
journal = "Climacteric",
issn = "1369-7137",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy

AU - Bruyniks, N.

AU - Nappi, R. E.

AU - Castelo-Branco, C.

AU - De Villiers, T. J.

AU - Simon, J.

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Objectives To determine whether assessment of all moderate-to-severe symptoms at baseline gives a more accurate evaluation of the treatment effect of ospemifene in vulvovaginal atrophy (VVA) than the most bothersome symptom (MBS) approach.Methods Data were pooled from two pivotal phase-III clinical trials evaluating the efficacy and safety of oral ospemifene 60 mg/day for the treatment of symptoms of VVA (n = 1463 subjects). Symptoms of vaginal dryness, dyspareunia, and vaginal and/or vulvar irritation/itching reported as moderate or severe at baseline were evaluated. Clinically relevant differences between ospemifene and placebo were analyzed using a four-point severity scoring system and presented as improvement, substantial improvement, or relief.Results Subjects in these studies reported statistically significant improvement, substantial improvement, and relief for vaginal dryness (p <0.00001), dyspareunia (p <0.001) and statistically significant improvement and relief for vaginal and/or vulvar irritation/itching (p <0.01) from baseline to week 12 with ospemifene compared with placebo. A similar trend was observed for women who reported substantial improvement of vaginal and/or vulvar irritation/itching.Conclusions For drug registration purposes, the use of the MBS model is appealing because of its simplicity and ease of scientific validation. However, the MBS model may underestimate the total magnitude of the clinical benefit of ospemifene treatment for symptomatic women suffering from VVA.

AB - Objectives To determine whether assessment of all moderate-to-severe symptoms at baseline gives a more accurate evaluation of the treatment effect of ospemifene in vulvovaginal atrophy (VVA) than the most bothersome symptom (MBS) approach.Methods Data were pooled from two pivotal phase-III clinical trials evaluating the efficacy and safety of oral ospemifene 60 mg/day for the treatment of symptoms of VVA (n = 1463 subjects). Symptoms of vaginal dryness, dyspareunia, and vaginal and/or vulvar irritation/itching reported as moderate or severe at baseline were evaluated. Clinically relevant differences between ospemifene and placebo were analyzed using a four-point severity scoring system and presented as improvement, substantial improvement, or relief.Results Subjects in these studies reported statistically significant improvement, substantial improvement, and relief for vaginal dryness (p <0.00001), dyspareunia (p <0.001) and statistically significant improvement and relief for vaginal and/or vulvar irritation/itching (p <0.01) from baseline to week 12 with ospemifene compared with placebo. A similar trend was observed for women who reported substantial improvement of vaginal and/or vulvar irritation/itching.Conclusions For drug registration purposes, the use of the MBS model is appealing because of its simplicity and ease of scientific validation. However, the MBS model may underestimate the total magnitude of the clinical benefit of ospemifene treatment for symptomatic women suffering from VVA.

KW - ospemifene

KW - randomized clinical trials

KW - Vulvar and vaginal atrophy

UR - http://www.scopus.com/inward/record.url?scp=84954026906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954026906&partnerID=8YFLogxK

U2 - 10.3109/13697137.2015.1113517

DO - 10.3109/13697137.2015.1113517

M3 - Article

AN - SCOPUS:84954026906

VL - 19

SP - 60

EP - 65

JO - Climacteric

JF - Climacteric

SN - 1369-7137

IS - 1

ER -